Business Insider
My Markets Watchlist
Markets Stocks

Novartis AG Stock , NVSEF

96.26 CHF +0.14 +0.15%
12:00:00 PM EDT 6/27/2025 BRX
News Analyst Data Analyst Opinions Insider Activity Dividend Calendar


Novartis Stock Snapshot

228.05 B
Market Cap in USD
1.90 B
Number of Shares
1.90 B
Total Number of Shares
3.50
Dividend in CHF
3.95
Dividend Yield
17.02
P/E Ratio
89.07
Free Float in %
5.21
EPS in CHF
20.21
Book Value per Share in CHF
7.62
Cash Flow per Share in CHF

Historical Prices for Novartis

Loading..
Date Open Close Daily High Daily Low
Price change over selected period: 0% 0

Novartis Analyst Opinions

  • All
  • Buy
  • Hold
  • Sell
Date Analyst Rating Price

Novartis Estimates* in USD

  2025 2026 2027 2028 2029
Revenue 54,170 55,302 56,580 58,609 59,338
Dividend 4.04 4.20 4.37 - 4.92
Dividend Yield (in %) 3.37 % 3.50 % 3.64 % 3.78 % 4.10 %
EPS 8.59 8.92 9.48 10.15 10.83
P/E Ratio 13.96 13.45 12.66 11.82 11.08
EBIT 21,284 21,136 22,098 23,294 24,427
EBITDA 21,972 22,348 23,194 24,587 28,548
Net Profit 17,063 17,483 18,228 19,292 19,592
Net Profit Adjusted 17,063 17,483 18,228 19,292 19,592
Pre-Tax Profit 20,085 - 21,585 21,907 23,227
Pre-Tax Profit Reported 16,320 17,004 17,883 20,343 23,984
EPS (Non-GAAP) ex. SOE - - - - -
EPS (GAAP) 6.88 7.30 7.78 - 9.71
Gross Income 44,236 45,665 46,406 50,029 50,962
Cash Flow from Investing -2,874 -2,157 -2,450 -2,026 -1,966
Cash Flow from Operations 18,881 19,694 19,954 22,589 23,712
Cash Flow from Financing -16,032 -11,327 -13,136 -14,128 -14,267
Cash Flow per Share 9.08 9.58 10.05 - 14.20
Free Cash Flow 15,288 15,872 16,053 17,951 19,424
Free Cash Flow per Share 7.14 7.84 8.38 11.63 12.73
Book Value per Share 23.89 26.53 29.51 - 30.90
Net Debt 16,219 11,081 5,515 2,228 -170
Research & Development Exp. 10,096 10,325 10,526 10,808 10,990
Capital Expenditure 2,515 2,700 2,868 2,485 2,070
Selling, General & Admin. Exp. 13,152 13,015 12,977 13,224 13,288
Shareholder’s Equity 45,365 49,150 53,433 53,403 62,116
Total Assets 91,660 108,779 112,904 110,858 118,298
  Previous Quarter
ending 03/31/25 		Current Quarter
ending 06/30/25 		Next Quarter
ending 09/30/25 		Current Year
ending 12/31/25 		Next Year
ending 12/31/26
Earnings Estimates
No. of Analysts - 7 7 19 19
Average Estimate - 2.307 USD 2.117 USD 8.594 USD 8.919 USD
Year Ago - 1.444 USD 1.373 USD 5.210 USD -
Publish Date - 7/17/2025 10/28/2025 - -
Revenue Estimates
No. of Analysts - 6 6 18 17
Average Estimate - 13,996 USD 13,390 USD 54,170 USD 55,302 USD
Year Ago - 11,317 USD 11,111 USD 44,313 USD -
Publish Date - 7/17/2025 10/28/2025 - -
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet

Income Statements in Mio. CHF

2024 2023 2022 2021 2020 2019 2018
Sales 44,312.55 40,834.74 48,273.77 47,199.92 45,672.01 47,202.69 50,792.58
Change of sales in % 8.52 -15.41 2.28 3.35 -3.24 -7.07 5.08
Gross profit on sales 32,842.74 29,535.99 33,655.54 32,693.25 31,479.23 32,867.38 32,778.34
Gross profit on sales change in % 11.20 -12.24 2.94 3.86 -4.22 0.27 4.29
Operating income 13,586.06 10,664.30 11,712.92 10,607.32 10,154.86 10,029.26 9,540.00
Operating income change in % 27.40 -8.95 10.42 4.46 1.25 5.13 5.53
Income before tax 12,045.77 8,210.08 8,003.45 9,872.25 8,639.94 8,229.51 7,239.17
Income before tax change in % 46.72 2.58 -18.93 14.26 4.99 13.68 -6.79
Income after tax 10,516.05 7,699.65 6,642.48 21,961.59 7,576.49 7,097.60 12,341.91
Income after tax change in % 36.58 15.92 -69.75 189.86 6.75 -42.49 62.78

Balance Sheet in Mio. CHF

2024 2023 2022 2021 2020 2019 2018
Total liabilities 56,764.78 48,036.33 57,678.82 62,014.69 66,758.56 60,872.42 66,003.25
Long-term liabilities per share 15.58 12.63 14.70 15.43 16.63 14.79 15.93
Equity 39,989.19 39,347.14 54,978.16 61,796.02 50,089.91 53,792.81 77,574.57
Equity change in % 1.63 -28.46 -10.93 23.21 -6.87 -30.68 7.22
Balance sheet total 96,753.97 87,383.47 112,656.98 123,810.71 116,848.47 114,665.23 143,577.83
Balance sheet total change in % 10.72 -22.43 -9.01 5.96 1.90 -20.14 10.59

Key Data in CHF

2024 2023 2022 2021 2020 2019 2018
Sales per share 21.78 19.52 21.97 20.88 19.89 20.35 21.67
P/E ratio (year end quote, basic EPS) 17.02 13.21 27.45 8.20 25.14 30.09 15.79
P/E ratio (year end quote, diluted EPS) 17.16 13.30 27.65 8.26 25.35 30.46 15.96
Dividend yield in % 3.95 3.89 3.83 3.86 3.59 3.21 3.39
Equity ratio in % 41.33 45.03 48.80 49.91 42.87 46.91 54.03
Debt ratio in % 58.67 54.97 51.20 50.09 57.13 53.09 45.97

Novartis Dividend Calendar

Date Name Dividend *yield Currency
2024 Novartis AG 3.50 3.95 CHF
2023 Novartis AG 3.30 3.89 CHF
2022 Novartis AG 3.20 3.83 CHF
2021 Novartis AG 3.10 3.86 CHF
2020 Novartis AG 3.00 3.59 CHF
2019 Novartis AG 2.95 3.21 CHF
2018 Novartis AG 2.85 3.39 CHF
2017 Novartis AG 2.80 3.40 CHF
2016 Novartis AG 2.75 3.71 CHF
2015 Novartis AG 2.70 3.11 CHF
2014 Novartis AG 2.60 2.82 CHF
2013 Novartis AG 2.45 3.44 CHF
2012 Novartis AG 2.30 4.00 CHF
2011 Novartis AG 2.25 4.19 CHF
2010 Novartis AG 2.20 4.00 CHF
2009 Novartis AG 2.10 3.72 CHF
2008 Novartis AG 1.89 3.79 USD
2007 Novartis AG 1.42 2.58 USD
2006 Novartis AG 1.11 1.93 USD
2005 Novartis AG 0.88 1.67 USD
2004 Novartis AG 0.92 1.83 USD
2003 Novartis AG 0.81 1.79 USD
2002 Novartis AG 0.69 1.89 USD
2001 Novartis AG 0.54 1.49 USD
2000 Novartis AG 0.53 1.19 USD
1999 Novartis AG 0.50 1.36 USD
*Yield of the Respective Date

Novartis Calendar

Event Estimate Info Date
Earnings Report 2.307 USD Q2 2025 Earnings Release 07/17/2025
Earnings Report 2.117 USD Q3 2025 Earnings Release 10/28/2025
Earnings Report 1.954 USD Q4 2025 Earnings Release 02/04/2026
Earnings Report 2.040 USD Q1 2026 Earnings Release 04/28/2026
Earnings Report 2.120 USD Q2 2026 Earnings Release 07/21/2026
Earnings Report 2.150 USD Q3 2026 Earnings Release 11/03/2026

Novartis Past Events

Event Actual EPS Info Date
Earnings Report 1.645 CHF Q1 2025 Earnings Release 04/29/2025
Annual General Meeting 5.214 CHF Annual General Meeting 03/07/2025
Earnings Report 1.246 CHF Q4 2024 Earnings Release 01/31/2025
Earnings Report 1.369 CHF Q3 2024 Earnings Release 10/29/2024
Earnings Report 1.447 CHF Q2 2024 Earnings Release 07/18/2024
Earnings Report 1.145 CHF Q1 2024 Earnings Release 04/23/2024
Annual General Meeting 6.425 CHF Annual General Meeting 03/05/2024
Earnings Report 3.673 CHF Q4 2023 Earnings Release 01/31/2024
Earnings Report 0.751 CHF Q3 2023 Earnings Release 10/24/2023
Earnings Report 0.998 CHF Q2 2023 Earnings Release 07/18/2023
Earnings Report 1.009 CHF Q1 2023 Earnings Release 04/25/2023
Annual General Meeting 3.047 CHF Annual General Meeting 03/07/2023
Earnings Report 0.665 CHF Q4 2022 Earnings Release 02/01/2023
Earnings Report 0.706 CHF Q3 2022 Earnings Release 10/25/2022
Earnings Report 0.743 CHF Q2 2022 Earnings Release 07/19/2022
Earnings Report 0.924 CHF Q1 2022 Earnings Release 04/26/2022
Annual General Meeting 9.792 CHF Annual General Meeting 03/04/2022
Earnings Report 6.721 CHF Q4 2021 Earnings Release 02/02/2022

Novartis Profile

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Moody’s Daily Credit Risk Score

Risk
  • Low
  • Medium
  • High
1
Moody’s Daily Credit Risk Score is a 1-10 score of a company’s credit risk, based on an analysis of the firm’s balance sheet and inputs from the stock market. The score provides a forward-looking, one-year measure of credit risk, allowing investors to make better decisions and streamline their work ow. Updated daily, it takes into account day-to-day movements in market value compared to a company’s liability structure.

Novartis Management

Name Job
Linda Kanitra Associate Director-Drug Development
Giovanni Caforio Chairman
Kees Roks Chief Audit Officer
Ingrid Zhang Chief Commercial Officer-International
Michelle Weese Chief Corporate Affairs Officer
Vasant Narasimhan Chief Executive Officer
Harry Werner Kirsch Chief Financial Officer
Karen L. Hale Chief Legal & Compliance Officer
Shreeram Aradhye Chief Medical Officer & President-Development
Robert Kowalski Chief People & Organization Officer
Aharon Gal Chief Strategy & Growth Officer
Korab Zuka Chief Sustainability Officer
Elizabeth McNally Director
Maria Victoria Cuevas-Pautonnier Director-Investor Relations & Head-ESG
Ton Büchner Independent Non-Executive Director
Frans van Houten Independent Non-Executive Director
Bridgette P. Heller Independent Non-Executive Director
John D. Young Independent Non-Executive Director
Ana de Pro Gonzalo Independent Non-Executive Director
Mary Elizabeth Doherty Independent Non-Executive Director
Nancy C. Andrews Independent Non-Executive Director
Daniel Hochstrasser Independent Non-Executive Director
Patrice Bula Lead Independent Non-Executive Director
Patrick Horber President-International
Steffen Lang President-Operations
Charlotte Pamer-Wieser Secretary
Marco Gadola Senior Auditor
Simon E. Moroney Vice Chairman
OSZAR »